{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:52:00Z","timestamp":1789865520108,"version":"4.0.1"},"reference-count":35,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T00:00:00Z","timestamp":1470268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p>Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC). Here, we analyze all episodes of agranulocytosis (<jats:italic>n<\/jats:italic>\u2009=\u2009161) and neutropenia (<jats:italic>n<\/jats:italic>\u2009=\u2009250) during deferiprone use in clinical trials (CT) and postmarketing surveillance programs (PMSP). Rates of agranulocytosis and neutropenia in CT were 1.5% and 5.5%, respectively. Of the agranulocytosis cases, 61% occurred during the first 6 months of therapy and 78% during the first year. These events appeared to be independent of dose, and occurred three times more often in females than males. Their duration was not significantly shortened by use of G\u2010CSF. No patient with baseline neutropenia (<jats:italic>n<\/jats:italic>\u2009=\u200912) developed agranulocytosis during treatment, which raises questions about the validity of prior neutropenia as a contraindication to use. Only 1\/7 novel neutropenia cases in CT progressed to agranulocytosis with continued treatment, indicating that neutropenia does not necessarily lead to agranulocytosis. The agranulocytosis fatality rate was 0% in CT and 15\/143 (11%) in PMSP. Rechallenge with deferiprone produced agranulocytosis in 75% of patients in whom the event had already occurred, and in 10% with previous neutropenia. Weekly ANC monitoring allows early detection and interruption of therapy, but does not prevent agranulocytosis from occurring. Its relevance appears to decrease after the first year of therapy, when agranulocytosis occurs less often. Based upon analysis of data collected over the past 20 years, it appears that patient education may be the key to minimizing agranulocytosis\u2010associated risks during deferiprone therapy. Am. J. Hematol. 91:1026\u20131031, 2016. \u00a9 2016 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24479","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T16:11:44Z","timestamp":1468512704000},"page":"1026-1031","source":"Crossref","is-referenced-by-count":62,"title":["Deferiprone\u2010induced agranulocytosis: 20 years of clinical observations"],"prefix":"10.1002","volume":"91","author":[{"given":"Fernando","family":"Tricta","sequence":"first","affiliation":[{"name":"ApoPharma Inc Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Uetrecht","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy University of Toronto Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Galanello","sequence":"additional","affiliation":[{"name":"Ospedale Regionale per la Microcitemia, ASL8, Cagliari  Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Connelly","sequence":"additional","affiliation":[{"name":"ApoPharma Inc Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rozova","sequence":"additional","affiliation":[{"name":"ApoPharma Inc Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spino","sequence":"additional","affiliation":[{"name":"ApoPharma Inc Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Palmblad","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Hematology Karolinska Institutet, Karolinska University Hospital Huddinge Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,4]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000243800"},{"key":"e_1_2_5_3_1","unstructured":"ApoPharma Inc. Ferriprox\u00ae US Prescribing Information (PI).http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021825lbl.pdf"},{"key":"e_1_2_5_4_1","unstructured":"ApoPharma Inc. Ferriprox\u00ae (Deferiprone) Summary of Product Characteristics (SmPC).http:\/\/ec.europa.eu\/health\/documents\/communityregister\/html\/h108.htm."},{"key":"e_1_2_5_5_1","first-page":"1","article-title":"Agranulocytosis due to deferiprone: A case report with cytomorphological and functional bone marrow examination","volume":"4","author":"Masera N","year":"2011","journal-title":"Blood Transfus"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12241"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01866.x"},{"key":"e_1_2_5_8_1","unstructured":"BertolaU CollellM PigaA et al. Neutropenia in homozygous b\u2010thalassemic patients on desferrioxamine (DFO) treatment. In: Proceedings of the 8th International Conference on Oral Chelation in the Treatment of Thalassemia and Other Diseases Corfu Greece;1997. p 90."},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2948"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3280"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24920"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181ec0f13"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08042.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-065805"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90641-7"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03554.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000243790"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000204494"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05274.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-7-200704030-00004"},{"key":"e_1_2_5_21_1","first-page":"79","article-title":"Combined chelation therapy in patients with thalassemia major: A fast and effective method of reducing ferritin levels and cardiological complications","volume":"3","author":"Farmaki K","year":"2002","journal-title":"Hematolo J"},{"key":"e_1_2_5_22_1","first-page":"81","article-title":"Combined iron chelation therapy with desferrioxamine in thalassemic patients","volume":"3","author":"Alymara V","year":"2002","journal-title":"Hematol J"},{"key":"e_1_2_5_23_1","first-page":"Pa120a","article-title":"Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia","volume":"100","author":"Kattamis A","year":"2002","journal-title":"Blood"},{"key":"e_1_2_5_24_1","unstructured":"BansalRK.Combined chelation with desferrioxamine and deferiprone in thalassemia major. In: Proceedings of 12th International Conference on Oral Chelation in the Treatment of Thalassemia and Other Diseases Santorini Hellas Vol. 120;2002. pp4\u20137."},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01002.x"},{"key":"e_1_2_5_26_1","first-page":"493","article-title":"Combined oral and parenteral iron chelation in beta thalssaemia major","volume":"55","author":"Balveer K","year":"2000","journal-title":"Med J Malaysia"},{"key":"e_1_2_5_27_1","first-page":"604","article-title":"Optimizing chelation therapy: Combining deferiprone and desferrioxamine","volume":"96","author":"Grady RW","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2326-9-3"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000007"},{"key":"e_1_2_5_30_1","first-page":"1","article-title":"Oral iron chelation","volume":"33","author":"Hoffbrand AV.","year":"1996","journal-title":"Semin Hematol"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.169.4.483"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/379519"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.985649"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07244"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2010.510831"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01323.x"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24479","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.24479","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:46:27Z","timestamp":1695501987000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,4]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1002\/ajh.24479"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24479","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,4]]}}}